Outsourcing
Cerba Research is fortunate to have skilled scientists with experience validating and testing these and other types of biomarkers. Its methods include, but are not limited to, flow cytometry, tissue immunohistochemistry (IHC), multiplex IHC, PCR, NGS, and cytokine and circulatory protein analysis, among others. This depth of experience enables the company to develop and validate both off-the-shelf and novel biomarkers.
Consistent sample handling ensures the quality of samples remains intact throughout the journey. Access to more than 700 labs and blood collection sites within the Cerba HealthCare Group, anchored by seven offices across five continents, allows Cerba Research to store specimens close to research sites while providing global logistics to and from our client’s sites and data analysis. To operate both globally and locally
“Cerba Research developed a global footprint to accommodate testing for research centres worldwide. Consistent sample handling ensures the quality of the samples remains intact.”
Cerba scientists team up with skilled researchers and physicians – experts who are treating patients every day – through partnerships with pathology and genomics labs, start-ups, and academia. With all these experiences and techniques under one roof, clients receive comprehensive insights more efficiently.
Global network value Delay when transporting specimens introduces risk of variability. To serve clinical research on a global level requires a network of instruments, platforms, and experts, with the ability to centralise the analysis and review data. Cerba Research developed a global footprint to accommodate testing for research centres worldwide.
requires world-class logistics and the result is minimised risk for clients. By analysing samples quickly, clients are ensured the highest quality data.
Close communication, scientist to scientist
A global network of labs also means access to a broad range of skilled laboratory researchers. In many cases, clients want to validate new tests or testing modalities. Cerba Research excels in developing and validating customised assays. However, whether it provides custom solutions or biomarkers from its vast portfolio depends on the outcome of an in-depth scientist-to- scientist discussion.
The company is keen to open the dialogue and to clients’ requirements. For
example, if you are developing a biomarker-guided oncology trial and have a clear idea of your needs, Cerba can accommodate, offering suggestions where it might bring value. If you have open-ended questions about biomarker development and validation, it can bring in technical, medical, and pathology experts to develop a solution. This level of close communication may start in drug discovery, but it continues through to commercialisation. It assists in development and validation from nonclinical through to Phase I-III clinical trials. The Cerba biomarker and companion diagnostic services operate in continuum, allowing you to fully optimise R&D productivity.
As clinical research becomes more biomarker-driven, the demand for companion diagnostics and results has increased. The therapy and the test must be addressed concurrently. To do so, Cerba Research calls upon its diagnostics business unit, which focuses on benchmark validation of new devices, reagents and biomarkers, and provides qualified – and often rare – specimens. Thanks to the network of Cerba HealthCare diagnostics labs, its also makes sure those tests will be routinely available to be accessed by patients when the drug is on the market. When combined with Cerba’s central laboratory solutions (specialty lab, FCM, ICH, NGS, BioA, metabolomics), additional translational science (CDx, biobanking), and IVD (biospecimens, prospective sample collection, IVD evaluation), clients gain additional value. Working with one vendor throughout drug development lowers risk by eliminating transfers, as well as improves administrative and operational efficiency: one vendor, one contract, one point of communication for multiple services. Given the promise of precision medicine to treat debilitating disease more effectively, we expect it to remain a focus of clinical research for the foreseeable future. As science and technology advance, Cerba Research will be here to provide comprehensive biomarker services, doing our part to change the shape of your clinical development. ●
Cerba HealthCare diagnostics labs makes sure specimen tests are routinely available. Clinical Trials Insight /
www.worldpharmaceuticals.net
www.cerbaresearch.com 47
gopixa/
Shutterstock.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53
